Douglas L. Noordsy, MD, is Clinical Professor, Director of Sports Psychiatry, and psychiatrist on the INSPIRE Early Psychosis Clinic in the Department of Psychiatry & Behavioral Sciences at Stanford University School of Medicine. Dr. Noordsy was previously Professor of Psychiatry, Director of Psychosis Services and Investigator in the Psychopharmacology Research Group at the Geisel School of Medicine at Dartmouth. His research interests include medication and psychosocial treatments for individuals with psychotic disorders, including those with co-occurring substance use disorders; methods to facilitate recovery and promote achievement of optimal outcomes for people with schizophrenia and bipolar disorder; rehabilitation and recovery interventions (including cognitive behavioral therapy and physical exercise); and methods to prevent progression of early psychotic disorders. He is particularly interested in the role of physical exercise for prevention of progression of early psychosis and for potentiating learning in CBTp and supported employment and education. Dr. Noordsy is a member of the Schizophrenia International Research Society, the International Early Psychosis Association, the American Medical Athletic Association, and the American Association of Community Psychiatrists, and is a fellow of the American Psychiatric Association. He is a member of the editorial advisory boards for Community Mental Health Journal, Case Reports in Psychiatry, American Medical Athletic Association Journal, and The Journal of Dual Diagnosis. Dr. Noordsy was recognized with the Exemplary Psychiatrist Award from the National Alliance on Mental Illness in 2001.
- Early psychosis
- Sports Psychiatry
- Lifestyle medicine
Clinical Professor, Psychiatry and Behavioral Sciences
Associate Chair of Clinical Integration and Coordination, Psychiatry & Behavioral Sciences (2016 - Present)
Director of Sports Psychiatry, Psychiatry & Behavioral Sciences (2015 - Present)
Board Certification: Psychiatry, American Board of Psychiatry and Neurology (1990)
Residency:Darmouth-Hitchcock Medical Center (1989) NH
M.D., Washington University School of Medicine, Medicine (1985)
B.S., St. Lawrence University, Chemistry (1981)
An RCT Evaluating the Effects of Skills Training and Medication Type on Work Outcomes Among Patients With Schizophrenia.
Although supported employment increases job acquisition for people with serious mental illness, data on participants' job tenure have been variable. This study evaluated the effects of a standardized work skills training program (the Workplace Fundamentals Module [WPFM]) on job tenure and other work outcomes among individuals receiving individual placement and support (IPS). The effects of two atypical antipsychotic medications on side effects were also tested. The primary hypothesis tested was that participants in IPS plus WPFM would have increased job tenure compared with those enrolled in IPS only, and the secondary hypothesis was that different antipsychotic medications would yield unique side effects.A 2×2 randomized controlled trial compared work outcomes, including job tenure, of participants receiving IPS with or without WPFM for up to two years after obtaining a job. Participants were also randomly assigned to olanzapine or risperidone. Measures of work outcomes, clinical status, and medication side effects were collected.Among 107 participants, 63% obtained at least one job. WPFM did not increase job tenure (51.53 and 41.37 total weeks worked for IPS only and IPS plus WPFM, respectively) or affect other work outcomes. Participants on olanzapine experienced increased body mass index, whereas those on risperidone lost weight, but medications did not differentially affect clinical or job outcomes.Clinic-based skills training did not improve work outcomes accruing from IPS. Risperidone, compared with olanzapine, may reduce body mass but has no differential effect on other work or clinical outcomes.
View details for PubMedID 27799019